13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001055951
Total reported value
$5.4B
$5.4B
110 檔
28.0%
At the close of Q1 2026, Orbimed Advisors LLC disclosed equity holdings valued at approximately $5.4B, spread across 110 reported holdings.
Orbimed Advisors LLC executed strategic sector rebalancing during Q1 2026, establishing 26 new positions while fully exiting 21 holdings and trimming 35 positions.
In terms of portfolio concentration, the top 5 core holdings (including EWTX, ELVN, MDXHEALTH SA) accounted for 28.0% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 10.02% | +1.73% | — | |
| 2 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.39% | +0.02% | — | |
| 3 | ✓ | Mdxhealth SA | Stock-Other | 5.86% | -5.86% | EXIT | |
| 4 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.46% | +1.30% | -21.38% | |
| 5 | RCEL | Avita Medical Inc | Stock-Other | 4.04% | -4.04% | EXIT | |
| 6 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.06% | -1.88% | -1.54% | |
| 7 | SION | Sionna Therapeutics Inc | Stock-Other | 2.90% | -0.80% | -0.87% | |
| 8 | AZN | AstraZeneca PLC | Stock-Healthcare | 2.71% | +0.48% | — | |
| 9 | MYGN | Myriad Genetics Inc | Stock-Other | 2.52% | -2.52% | EXIT | |
| 10 | MBX | Mbx Biosciences Inc | Stock-Other | 2.23% | +1.30% | -7.56% | |
| 11 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 2.15% | -0.16% | — | |
| 12 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.05% | -0.44% | -6.23% | |
| 13 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.02% | -0.61% | -38.25% | |
| 14 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.97% | -0.80% | -20.77% | |
| 15 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.65% | -1.03% | — | |
| 16 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.64% | -0.05% | — | |
| 17 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.46% | +0.75% | +26.99% | |
| 18 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.43% | +0.53% | — | |
| 19 | IRON | Disc Medicine Inc | Stock-Other | 1.40% | -0.91% | — | |
| 20 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.36% | -0.12% | — | |
| 21 | CGON | Cg Oncology Inc | Stock-Other | 1.32% | -0.03% | -37.47% | |
| 22 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.26% | -0.26% | +137.02% | |
| 23 | SYK | Stryker CORP | Stock-Healthcare | 1.23% | -0.30% | -43.85% | |
| 24 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.15% | -0.16% | +19.35% | |
| 25 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.14% | -0.08% | +109.39% | |
| 26 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.14% | +0.30% | +82.54% | |
| 27 | PFE | Pfizer Inc | Stock-Healthcare | 1.12% | -1.12% | EXIT | |
| 28 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.08% | +0.26% | +32.50% | |
| 29 | NTRA | Natera Inc | Stock-Healthcare | 1.07% | +0.26% | -28.38% | |
| 30 | ABVX | Abivax Sa-adr | Stock-Other | 1.06% | +0.79% | +26.58% | |
| 31 | UPB | Upstream Bio Inc | Stock-Other | 1.05% | -0.32% | — | |
| 32 | DHR | Danaher CORP | Stock-Healthcare | 1.03% | -1.03% | EXIT | |
| 33 | CAI | Caris Life Sciences Inc | Stock-Other | 1.03% | -0.10% | -9.92% | |
| 34 | ASND | Ascendis Pharma A/S | Stock-Other | 0.85% | -0.85% | EXIT | |
| 35 | STTK | Shattuck Labs Inc | Stock-Other | 0.83% | -0.01% | — | |
| 36 | GH | Guardant Health Inc | Stock-Healthcare | 0.82% | +0.81% | — | |
| 37 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.81% | -0.71% | -58.80% | |
| 38 | PRLD | Prelude Therapeutics Inc | Stock-Other | 0.76% | +0.60% | — | |
| 39 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.74% | -0.04% | — | |
| 40 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.74% | -0.20% | -15.49% | |
| 41 | QURE | uniQure N.V. | Stock-Other | 0.72% | +0.83% | +189.69% | |
| 42 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.70% | -0.29% | -26.03% | |
| 43 | ELV | Elevance Health Inc | Stock-Healthcare | 0.69% | +0.21% | +15.74% | |
| 44 | RLMD | Relmada Therapeutics Inc | Stock-Other | 0.67% | -0.20% | +80.64% | |
| 45 | FBRX | Forte Biosciences Inc | Stock-Other | 0.64% | -0.02% | — | |
| 46 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.60% | -0.10% | -23.08% | |
| 47 | ESPR | Esperion Therapeutics Inc | Stock-Other | 0.59% | -0.59% | EXIT | |
| 48 | NPCE | Neuropace Inc | Stock-Other | 0.57% | -0.11% | -12.87% | |
| 49 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.56% | +0.11% | +30.98% | |
| 50 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.47% | +0.48% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Mdxhealth SA | +5.9% | NEW | New buy |
| 2 | RCEL | Avita Medical Inc | +4% | NEW | New buy |
| 3 | ELVN | Enliven Therapeutics Inc | +3.8% | — | Unchanged |
| 4 | AZN | AstraZeneca PLC | +2.7% | NEW | New buy |
| 5 | MYGN | Myriad Genetics Inc | +2.5% | NEW | New buy |
| 6 | EWTX | Edgewise Therapeutics Inc | +1.9% | — | Unchanged |
| 7 | MRK | Merck & Co. Inc. | +1.6% | NEW | New buy |
| 8 | CRVS | Corvus Pharmaceuticals Inc | +1% | — | Unchanged |
| 9 | XENE | Xenon Pharmaceuticals Inc | +0.8% | +137.02% | Add |
| 10 | GH | Guardant Health Inc | +0.8% | NEW | New buy |
| 11 | PRAX | Praxis Precision Medicines I | +0.6% | +82.54% | Add |
| 12 | PVLA | Palvella Therapeutics Inc | +0.5% | NEW | New buy |
| 13 | SNDX | Syndax Pharmaceuticals Inc | +0.5% | NEW | New buy |
| 14 | STRO | Sutro Biopharma Inc | +0.4% | NEW | New buy |
| 15 | NKTR | Nektar Therapeutics | +0.4% | NEW | New buy |
| 16 | RLMD | Relmada Therapeutics Inc | +0.4% | +80.64% | Add |
| 17 | MLYS | Mineralys Therapeutics Inc | +0.4% | +109.39% | Add |
| 18 | QURE | uniQure N.V. | +0.4% | +189.69% | Add |
| 19 | STTK | Shattuck Labs Inc | +0.3% | — | Unchanged |
| 20 | DFTX | Definium Therapeutics Inc | +0.3% | NEW | New buy |
| 21 | AMGN | Amgen Inc | +0.3% | NEW | New buy |
| 22 | ALHC | Alignment Healthcare Inc | +0.3% | NEW | New buy |
| 23 | BMY | Bristol-myers Squibb Co | +0.3% | +19.35% | Add |
| 24 | PFE | Pfizer Inc | +0.3% | +17.76% | Add |
| 25 | REGN | Regeneron Pharmaceuticals | +0.2% | NEW | New buy |
| 26 | BIIB | Biogen Inc | +0.2% | NEW | New buy |
| 27 | QGEN | Qiagen N.V. | +0.2% | NEW | New buy |
| 28 | BCAX | Bicara Therapeutics Inc | +0.2% | +219.13% | Add |
| 29 | DYN | Dyne Therapeutics Inc | +0.2% | +32.50% | Add |
| 30 | GILD | Gilead Sciences Inc | +0.2% | NEW | New buy |
| 31 | HRTX | Heron Therapeutics Inc | +0.2% | NEW | New buy |
| 32 | AVBP | Arrivent Biopharma Inc | +0.1% | — | Unchanged |
| 33 | QTTB | Q32 Bio Inc | +0.1% | — | Unchanged |
| 34 | CMPS | Compass Pathways PLC | +0.1% | NEW | New buy |
| 35 | ESPR | Esperion Therapeutics Inc | +0.1% | +77.19% | Add |
| 36 | ALXO | Alx Oncology Holdings Inc | +0.1% | NEW | New buy |
| 37 | AORT | Artivion Inc | +0.1% | NEW | New buy |
| 38 | PRLD | Prelude Therapeutics Inc | +0.1% | — | Unchanged |
| 39 | ASND | Ascendis Pharma A/S | +0.1% | +5.81% | Add |
| 40 | WHWK | Whitehawk Therapeutics Inc | +0.1% | — | Unchanged |
| 41 | ORIC | Oric Pharmaceuticals Inc | +0.1% | -26.03% | Trim |
| 42 | SVRA | Savara Inc | +0.1% | NEW | New buy |
| 43 | SLNOEUR | Soleno Therapeutics Inc | +0.1% | NEW | New buy |
| 44 | LFST | Lifestance Health Group Inc | +0.1% | NEW | New buy |
| 45 | CRBP | Corbus Pharmaceuticals Holdi | +0.1% | +8.76% | Add |
| 46 | RVMD | Revolution Medicines Inc | +0.1% | +100.77% | Add |
| 47 | DRUG | Bright Minds Biosciences Inc | +0.1% | NEW | New buy |
| 48 | PTGX | Protagonist Therapeutics Inc | +0.1% | +94.01% | Add |
| 49 | BTSG | Brightspring Health Services | 0% | +1.90% | Add |
| 50 | BIOA | Bioage Labs Inc | 0% | -10.00% | Trim |
According to official SEC Form 13F filings, Orbimed Advisors LLC reported a total U.S. public equity portfolio value of $5.4B across 110 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
MDXHEALTH SA
市值: $285.9M
Top Position Liquidated / Trimmed
430
前期市值: $87.0M
During Q1 2026, Orbimed Advisors LLC's top holdings by market value included EWTX (10.0%)、ELVN (6.4%)、MDXHEALTH SA (5.9%). The largest single position, EWTX, represented 10.0% of total portfolio value.
In Q1 2026, Orbimed Advisors LLC made 106 total portfolio adjustments, initiating 26 new buys, adding to 24 positions, trimming 35 holdings, and fully liquidating 21 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.